Terminated PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT02575807

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (SEASCAPE)

A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

Sponsor: Aduro Biotech, Inc.

Conditions Platinum-resistant Fallopian Cancer Platinum-resistant Ovarian Cancer Platinum-resistant Peritoneal Cancer

Interventions CRS-207 Epacadostat Pembrolizumab

Updated 11 times since 2017 Last updated: Apr 1, 2019 Started: Mar 8, 2016 Primary completion: Apr 26, 2018 Completion: May 8, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was stopped due to low enrollment and lack of clinical activity.

Other terminated trials from Aduro Biotech, Inc.

More terminations from Aduro Biotech, Inc.

A PHASE1/PHASE2 clinical study on Platinum-resistant Fallopian Cancer and Platinum-resistant Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by Aduro Biotech, Inc. and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

May 2019 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Jun 2018 — May 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2017 — Dec 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Jul 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aduro Biotech, Inc.
Incyte Corporation

Data source: Aduro Biotech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Charlottesville, United States , Chicago, United States , Gainesville, United States , Montreal, Canada , Philadelphia, United States , Portland, United States , Scottsdale, United States , Seattle, United States , Stanford, United States and 1 more location